Basal Insulin in Vulnerable Patients with Type 2 Diabetes

The Physiologic Rationale for Optimizing HA1c Target Goal Attainment with Basal Insulin CME Course

The Physiologic Rationale for Optimizing HA1c Target Goal Attainment with Basal Insulin

Mechanisms, Patient Selection and Sequencing Strategies - Why Long-Acting Insulin Matters as a Foundational Approach for the Diabetes and Endocrine Specialist: Addressing Challenges in Complex and Vulnerable Patients with T2D Vivian ...
Vivian A. Fonseca, MD, FRCP

Vivian A. Fonseca, MD, FRCP

Optimizing Glycemic Control While Mitigating Hypoglycemic Risk in Challenging Patients with T2D CME Course

Optimizing Glycemic Control While Mitigating Hypoglycemic Risk in Challenging Patients with T2D

Why, When, and in Whom Do ADA/EASD Guidelines Recommend “Physiologic” Basal Insulin for T2D? The Evidence for the Safety and Efficacy of Long-Acting Insulin Pablo F. Mora, MD, MSc, FACE, CDE
Pablo Mora, MD, FACE

Pablo Mora, MD, FACE

Basal Insulin, Interactive (ARS) Case Management Session #1: Applying Updated ADA/EASD Guidelines to an Early-Onset Patient with T2D CME Course

Basal Insulin, Interactive (ARS) Case Management Session #1: Applying Updated ADA/EASD Guidelines to an Early-Onset Patient with T2D

The Patient Who Has Not Achieved Ideal HA1c Levels after Metformin Alone and/or Metformin plus an SGLT-2 Inhibitor Pablo F. Mora, MD, MSc, FACE, CDE
Pablo Mora, MD, FACE

Pablo Mora, MD, FACE

Basal Insulin, Interactive (ARS) Case Management Session #2: Optimizing Glycemic Control in the Older or Elderly Patient with T2D at Risk for Hypoglycemia CME Course

Basal Insulin, Interactive (ARS) Case Management Session #2: Optimizing Glycemic Control in the Older or Elderly Patient with T2D at Risk for Hypoglycemia

What is the Mechanistic Rationale for Early Initiation of a Physiologic, Basal Insulin in Vulnerable Patients Who Require Intensified Glycemic Control? How Do the Physiology and the Studies Guide Us? What Sequencing Strategies Make Most ...
Guillermo E. Umpierrez, MD, CDE

Guillermo E. Umpierrez, MD, CDE

Didactic Presentation including Real Time Video Demonstration - Modifying Insulin Therapy in Complex and Vulnerable Patients: Practical Approaches for Switching to a Physiologic, Basal Insulin Formulation CME Course

Didactic Presentation including Real Time Video Demonstration - Modifying Insulin Therapy in Complex and Vulnerable Patients: Practical Approaches for Switching to a Physiologic, Basal Insulin Formulation

In Whom, When and How? Optimizing Safety and Regimen Adherence with Improved Devices, Formulations, Dosing Vigilance and Delivery Systems for Long-Acting Insulin Juan P. Frias, MD, FACE
Juan P. Frias, MD, FACE

Juan P. Frias, MD, FACE

Basal Insulin, Interactive (ARS) Case Mangemement Session #3 CME Course

Basal Insulin, Interactive (ARS) Case Mangemement Session #3

Presentations, interactive discussion, and evaluation of two patients who have been on various insulin formulations who present with specific clinical profiles, safety needs, and glycemic dysregulation issues that make them ideal candidates ...
Juan P. Frias, MD, FACE

Juan P. Frias, MD, FACE

Program Chair Summary: The Current and Future Roadmap to Optimizing Glycemic Control in T2D with Physiologic, Long-Acting Basal Insulin The Evidence - Guideline, and Mechanistic Rationale for Long-Acting, Physiologic Basal Insulin CME Course

Program Chair Summary: The Current and Future Roadmap to Optimizing Glycemic Control in T2D with Physiologic, Long-Acting Basal Insulin The Evidence - Guideline, and Mechanistic Rationale for Long-Acting, Physiologic Basal Insulin

Improving on the Safety (Risk of Hypoglycemia) and Efficacy Equation for Insulin-Based Glycemic Control — A Practical Roadmap for the Front Lines of Diabetes Specialty Practice Vivian A. Fonseca, MD, FRCP – Program Chair
Vivian A. Fonseca, MD, FRCP

Vivian A. Fonseca, MD, FRCP

Program Medium

Internet-based program

 

Estimated Time to Complete Educational Activity

2.5 hours

 

Course Overview

In this web-based program, physicians and optometrists will learn how recent developments have helped to advance the management of Type 2 diabetes

 

Release Date

July, 18, 2017

 

Expiration Date

July 18, 2019

 

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period July, 18, 2017  through July 18, 2019 participants must:
1) read the learning objectives and faculty disclosures;
2) study the educational activity, and are expected to view all 9 segments totaling 2.5 hours to successfully complete the activity and earn CME credit;
3) register and complete the evaluation form and post-test;
4) score 100% on the post-test; and
5) print out your CME certificate.

 

Registration

Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

 

Grantor Support

Supported by an educational grant from Sanofi Diabetes

 

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School and CMEducation Resources, LLC. ‘The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

 

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Policy on Faculty & Provider Disclosure

University of Massachusetts Medical School requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to University of Massachusetts Medical School policy.  The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

 

Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCM.

 

Program Faculty and Disclosure

VIVIAN A. FONSECA, MD, FRCP
Program Chair
Professor of Medicine and Pharmacology
Tulis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA
 
Research Support (To Tulane): Grants from Asahi, Bayer
Consulting and Speaking: Takeda, Novo Nordisk, Sanofi-aventis, Eli Lilly, Astra-Zeneca, Janssen
 
JUAN P. FRIAS, MD, FACE
Clinical Assistant Professor of Medicine
University of California
President
National Research Institute
Los, Angeles, California
 
Consulting: Astra Zeneca, BMS, Johnson and Johnson, Novo Nordisk, Sanofi
Speaker’s Bureau: Sanofi, Eli Lilly, Novo Nordisk, Astra Zeneca
Contracted Research: AbbVie, AstraZeneca, Boehringer Ingelheim, BMS, Elcelyx, Eli Lilly, IONIS, Janssen, Johnson and Johnson, Ligand, Merck, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi, Theracos, vTv
 
GUILLERMO E. UMPIERREZ, MD, CDE
Professor of Medicine
Emory University School of Medicine
Physician
Emory University Hospital/Grady Health System
Atlanta, GA 

Nothing to disclose 

 

PABLO F. MORA, MD, MSc, FACE, CDE
Adjunct Associate Professor
University of Texas Southwestern Medical Center at Dallas
Staff Endocrinologist
Diabetes America (Plano)
Plano, Texas

Consultant and Speaker’s Bureau: Novo Nordisk

 

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Apply national guidelines, including the non-strictly algorithmic and flexibly prescriptive 2012 ADA/ EASD Guidelines focused on comprehensive management of diabetes; and identify therapeutic options, based on objective triggers—number and type of OADs, patient needs and preferences, target goal attainment, and other factors—consisting of oral, basal insulin-, and/or combined oral-insulin regimens that provide guideline-consistent care for this population. 
  • Explain the physiologic basis of long-acting insulin formulations and how mimicking physiologic insulin triggers and time-activity profiles may improve efficacy and safety of long-acting formulations; 
  • Identify patients with T2D who are not meeting target goals for HbA1 and/or other targets require initiation with or who require intensification with basal insulin therapy; 
  • Assess and calculate the risks of hypoglycemia in their patients with T2D, counsel their patients on recognizing symptoms of hypoglycemia, and select among therapeutic agents, including established and longer-acting basal insulin-based therapies and combination oral-insulin-based treatments that may reduce the risk of hypoglycemia in this patient subgroup; 
  • Understand how new basal insulin formulations in development or recently introduced into clinical use may help reduce the risk of hypoglycemia associated with insulin use;

 

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

 

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

• We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.

• For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.

• We may use the Information to send you information about other CME activities that CMEducation Resources is offering.

• If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.

• You should check this privacy policy periodically to see whether we have made any changes